5:27 PM
 | 
Jan 12, 2018
 |  BioCentury  |  Strategy

Remapping growth

How restructured Alnylam, Sanofi deal generates more value for both companies

As patisiran and fitusiran get closer to market, Alnylam Pharmaceuticals Inc. and Sanofi Genzyme concluded that the territorial complexity of their partnership for the products would limit their commercial value. Amendments announced on Jan. 7 will remove the geographic shackles and place the products with the partner best-suited to maximize their growth worldwide.

Patisiran and fitusiran are the most advanced molecules in the 2014 collaboration to co-develop and co-commercialize rare disease RNAi therapeutics discovered by Alnylam. Under the restructured deal, Alnylam gained worldwide rights to patisiran, an IV RNAi therapeutic targeting the transthyretin (TTR) gene using second-generation lipid nanoparticle (LNP) technology, and its follow-on molecule ALN-TTRsc02. Sanofi gained worldwide rights to fitusiran, which targets anti-thrombin III (AT3; SERPINC1) mRNA.

“This was about being pragmatic about how you create the most value for these products,” Bill Sibold, EVP and head of Sanofi Genzyme, told BioCentury. “To get the most value from the programs, we needed to take it from a geographic focus to a product focus. This new structure allows Alnylam to focus on TTR and us to focus on hemophilia.”

Under the original deal, Alnylam had commercialization rights to patisiran in the U.S., Canada and Western Europe, and the partners shared commercialization rights in those territories to fitusiran and ALN-TTRsc02. The Sanofi unit had rights to all three products elsewhere. At the time, patisiran had just started Phase...

Read the full 1128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >